FDA approves Myxredlin, first ready-to-use insulin for intravenous infusion
Food and Drug Administration has approved Myxredlin, the first ready-to-use insulin for intravenous (IV) infusion for use in acute care settings under medical supervision.
The U.S. Food and Drug Administration (FDA) has granted approval of Myxredlin (Insulin Human in 0.9% Sodium Chloride Injection). Myxredlin (
"Insulin is in the top five drug classes involved with medication errors, and more than 30 percent of those errors result in patient harm,"1 said Robert Felicelli, president, Pharmaceuticals, Baxter. “When a patient requires intravenous insulin in the hospital, pharmacists have to manually admix insulin for treatment. With the launch of Myxredlin, clinicians will have access to a convenient, reliable presentation of ready-to-use insulin that can help ensure faster delivery to patients, streamlined workflow for pharmacists and nurses, and less waste for hospitals."
Myxredlin is indicated for use as a short-acting human insulin to improve glycemic control in adults and pediatric patients with diabetes mellitus. Myxredlin is intended for use only in acute care settings under medical supervision.
Myxredlin is a short-acting human insulin indicated to improve glycemic control in adults and pediatric patients with diabetes mellitus.
- During episodes of hypoglycemia
- Hypersensitivity to insulin human or any of the excipients in Myxredlin
Warnings and Precautions
- Administer Myxredlinintravenou
sly ONLY under medical supervision with close monitoring of blood glucose and potassium levels. Hypokalemia may be life-threatening.